Prominent cognitive deficits, brain fog associated with COVID-19


The investigators reported the following most prominent cognitive deficits: processing speed, executive functioning, and phonemic fluency among others.

High rate of cognitive impairment, brain fog associated with COVID-19

Jacqueline Becker, PhD, from the Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, and colleagues reported a “relatively high frequency of cognitive impairment several months after patients contracted COVID-19,” which patients have described as brain fog.

Dr. Becker, first author of the article, and colleagues investigated the rates of cognitive impairment in a cross-sectional study1 of survivors of COVID-19 who had been treated in outpatient, emergency department, or inpatient hospital settings and identified through the Mt. Sinai Health System registry. All patients had tested positive for SARS-CoV-2 or had serum antibody positivity and no history of dementia. The study was conducted from April 2020 through May 2021.

The patients’ cognitive functioning was assessed using the following neuropsychological measures: Number Span forward (attention) and backward (working memory), Trail Making Test Part A and Part B (processing speed and executive functioning, respectively), phonemic and category fluency (language), and the Hopkins Verbal Learning Test–Revised (memory encoding, recall, and recognition), the investigators recounted. The impairment on each scale was defined as a z score of ≤1.5 standard deviations below the specific measurements for age, educational level, and sex-adjusted norms.

A total of 740 participants were included in the study (63% women; mean age, 49 years; range, 38-59). More than half of patients were Caucasian (54%), followed by Hispanic (20%), and Black (15%); the rest were multiracial and other (including Asian). The mean time from establishment of the COVID-19 diagnosis was 7.6 months.

The investigators reported the following most prominent cognitive deficits: processing speed (18%, n = 133), executive functioning (16%, n = 118), phonemic fluency (15%, n = 111), and category fluency (20%, n = 148), memory encoding (24%, n = 178), and memory recall (23%, n = 170).

Adjusted analyses showed that “hospitalized patients were more likely to have impairments in attention (odds ratio [OR]: 2.8; 95% confidence interval [CI]: 1.3-5.9), executive functioning (OR: 1.8; 95% CI: 1.0-3.4), category fluency (OR: 3.0; 95% CI: 1.7-5.2), memory encoding (OR: 2.3; 95% CI: 1.3-4.1), and memory recall (OR: 2.2; 95% CI: 1.3-3.8) than those in the outpatient group.”

In contrast, patients treated in the Emergency Department had impaired category fluency (OR: 1.8; 95% CI: 1.1-3.1) and memory encoding (OR: 1.7; 95% CI: 1.0-3.0) compared with patients treated on an outpatient basis. No significant differences in impairments in other domains were observed between groups.

The investigators noted that the results, i.e., the association of COVID-19 with executive functioning, raises questions about long-term treatment and emphasized the importance of future studies to identify the risk factors and mechanisms underlying cognitive dysfunction and rehabilitation options.

1. Becker JH, Lin JJ, Doernberg M, et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open 2021;4(10):e2130645. doi:10.1001/jamanetworkopen.2021.30645
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.